galenexib

Galenexib is a patent-pending small molecule drug candidate being developed by PharmassêtX. Positioned under a "one asset, many markets" strategy, the drug is intended for broad therapeutic applications across several disease areas, including pouchitis, inflammatory bowel disease (IBD), viral and infectious diseases, metabolic and cardiovascular disorders, neurodegenerative diseases, and autoimmune conditions. The U.S. FDA has granted galenexib Orphan Drug designation for the treatment of pouchitis, which provides the developer with seven years of market exclusivity upon potential approval. Currently in the preclinical stage of development, galenexib is projected to generate significant commercial revenue starting in 2029, with a risk-adjusted net present value (rNPV) estimated at over $100 million.